Compare Amphastar Pharmaceuticals Inc (AMPH) vs Workday Inc (WDAY) Price & Performance

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Workday (WDAY) trades at $179.64, up 5.52% over 24 hours, reflecting strong momentum. The stock shows bullish technical signals with moving averages supporting an uptrend, while RSI levels indicate potential overbought conditions. Fundamentally, the company has consistently beaten earnings expectations, with Q1 2026 EPS of $2.66 surpassing estimates of $2.51. Revenue growth is robust, projected to rise from $8.45B in 2025 to $9.9B in 2026, though net income margins have fluctuated. Recent news highlights partnerships and product launches, such as the Workday Adaptive Planning FedRAMP authorization announced on July 23, 2026.

The outlook for WDAY is positive, driven by earnings beats and strategic AI integrations, but elevated valuation ratios like a P/E of 55.96 pose risks. Investors should weigh growth potential against competitive pressures and market volatility, with analyst consensus leaning bullish but caution advised near technical resistance levels.